The widening controversy over access to abortion medications draws a Congressional query to UPS, FedEx and DHL
Numerous state laws have been passed or proposed in the wake of the US Supreme Court's decision to remove constitutional protections to abortion. Potentially, these laws could enable prosecutors to gain access to who has provided access to, or received, abortion medications. One response, from a group of members of the US Congress, is to seek meetings with package delivery companies "to ensure individuals' rights to privacy and protection against unreasonable search and seizure are upheld" by the delivery companies, according to a statement by the Representatives (Raja Krishnamoorthi [D-IL], Dean Phillips [D-MN], Ayanna Pressley [D-MA], Katie Porter [D-CA] and Cori Bush [D-MO]).
Some abortion medications are available over the counter, depending on the state; other states require a physician’s or pharmacist’s authorization. Mail order is possible in most cases. A variety of anti-abortion medications are FDA-approved—which precludes states making possession of them illegal. Meanwhile, the intent of some anti-abortion state laws is to enable criminal investigation of the delivery or use of such medications; even telemedicine is being drawn into the controversy. Even before some of these laws are tested for their constitutional legality, the five Representatives want to clarify how the delivery companies will meet such investigations. Specifically, they want policies to require search warrants before access to shipments are granted; to not voluntarily reveal such shipments; to control and quickly delete data recording such shipments; and to limit the collection of such data.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.